The Role of the GP in the Management of Ambulatory Heart Failure
Recruiting
- Conditions
- Heart Failure
- Registration Number
- NCT05056649
- Lead Sponsor
- Jean-Marc BOIVIN
- Brief Summary
To describe the causes mentioned by general practitioners, explaining the under-treatment of the three main treatments for heart failure with impaired ejection fraction (ARS blockers of the type ACEinhibitor/ARA2/ARNi, ß- and/or anti-aldosterone).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Patients with a previous diagnosis of heart failure with impaired ejection fraction (LVEF < 40%)
- Under 85 years of age
- Admitted to an Emergency department for cardiac decompensation
- Hospitalized following this decompensation
- Not deceased within one month of hospitalisation
- Whose sum of the doses of ACEI or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient* (definition in annex)
- Who did not object within one month of being informed
Exclusion Criteria
- Patient objecting to the use of their data
- Patient who is a minor
- Patient who does not have a general practitioner
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quantitative analysis of verbatims after grouping Through study completion, an average of 1 year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms contribute to under-treatment of ARS blockers in heart failure with reduced ejection fraction (HFrEF) patients managed by GPs?
How does the effectiveness of ACE inhibitors, ARBs, and ARNis compare to standard-of-care therapies in ambulatory HFrEF management?
What biomarkers are associated with GP decision-making in prescribing ß-blockers and anti-aldosterones for heart failure patients?
What adverse events are commonly reported with ARS blockers, ß-blockers, and anti-aldosterones in primary care heart failure management?
Are there combination therapies or alternative drug classes that could improve adherence to HFrEF treatment guidelines in primary care settings?
Trial Locations
- Locations (1)
CHRU of Nancy
🇫🇷Vandœuvre-lès-Nancy, France
CHRU of Nancy🇫🇷Vandœuvre-lès-Nancy, FranceJean-Marc BOIVIN, MD, PhDPrincipal Investigator